摘要
目的:探讨信迪利单抗与贝伐珠单抗联合紫杉醇加顺铂方案对晚期宫颈癌患者的治疗效果以及不良反应的影响。方法:回顾性选取130例晚期宫颈癌患者,按照治疗方式的不同分为对照组(n=68)和观察组(n=62),对照组采用TP方案治疗,观察组使用信迪利单抗与贝伐珠单抗联合TP方案治疗,对比两组患者肿瘤标志物、血清和免疫相关因子、生活质量评分、临床疗效和不良反应情况。结果:治疗后,观察组癌胚抗原(CEA)、糖类抗原(CA)125、CA199、CA724、鳞状细胞癌抗原(SCCA)水平低于对照组(P<0.05);血管内皮生长因子(VEGF)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)、分化抗原簇105(CD105)、存活蛋白(survivin)水平低于对照组(P<0.05);辅助性T细胞(Th)17、Th1/Th2、调节性T细胞(Treg)低于对照组,CD4+/CD8+高于对照组(P<0.05);宫颈癌生活质量评价量表(FACT-Cx)评分高于对照组(P<0.05);观察组临床治疗总有效率(82.26%)高于对照组(66.18%,P<0.05);治疗期间两组患者不良反应总发生率比较无统计学差异(P>0.05)。结论:信迪利单抗与贝伐珠单抗联合TP方案对晚期宫颈癌患者治疗效果显著,且不增加不良反应发生风险。
Objective:To investigate the efficacy and adverse reactions of sintilimab and bevacizumab in combination with taxol cisplatin(TP)regimen in patients with advanced cervical cancer.Methods:One hundred and thirty patients with advanced cervical cancer were divided into a control group(n=68)and an observation group(n=62)according to different treatment methods.The control group was treated with TP regimen,while the observation group was treated with TP+sintilimab+bevacizumab.The therapeutic effect,tumor markers,serum and immune-related factors,quality of life and adverse reactions were compared between the two groups.Results:After treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen(CA)125,CA199,CA724 and squamous cell carcinoma antigen(SCCA)in the observation group were lower than those in the control group(P<0.05);and the levels of vascular endothelial growth factor(VEGF),cytokeratin 19 fragment antigen 21-1(CYFRA21-1),cluster of differentiation 105(CD105)and Survivin were lower than those in the control group(P<0.05);and the number of helper T cells(Th)17,Th1/Th2 and regulatory T cells(Treg)were lower and CD4+/CD8+was higher in the control group(P<0.05);and the score of FACT-Cx was higher than that of control group(P<0.05);and the total effective rate of observation group(82.26%)was higher than that of control group(66.18%,P<0.05);there was no significant difference in the total incidence of adverse reactions between the two groups during the treatment(P>0.05).Conclusion:Sintilimab and bevacizumab in combination with taxol cisplatin regimen is effective in the treatment of patients with advanced cervical cancer without the increasing the risk of adverse reactions.
作者
陈苹
岳青芬
李晓宁
CHEN Ping;YUE Qing-fen;LI Xiao-ning(Luoyang Central Hospital,Zhengzhou University,Luoyang 471000,China;不详)
出处
《中国合理用药探索》
2025年第5期49-54,共6页
Chinese Journal of Rational Drug Use
基金
河南省科技发展计划(222102310049)。
